Meeting
2019 Genitourinary Cancers Symposium
Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study.
Authors
Nicholas Salgia
City of Hope, Duarte, CA
Nicholas Salgia , Sumanta K. Pal , Vincent Chung , Scott T. Tagawa , Joel Picus , Hani M. Babiker , Sumati Gupta , Raymond Couric Wadlow , Julie Poore , Christine Peterson , Ely Benaim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02030067
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 455)
DOI
10.1200/JCO.2019.37.7_suppl.455
Abstract #
455
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).
First Author: Jacob Adashek
Poster
2018 Genitourinary Cancers Symposium
RX‐3117, an oral hypomethylating agent to treat advanced solid tumors: Interim results from an ongoing phase 2a study in advanced urothelial cancer (aUC).
First Author: Meghan Salgia
Poster
2021 Gastrointestinal Cancers Symposium
Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
First Author: Jennifer J. Knox
Poster
2018 Gastrointestinal Cancers Symposium
RX3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer—Preliminary results of stage II of the phase Ia/IIb study.
First Author: Vincent M. Chung